Crizotinib/Moderate CYP3A4 Inducers that Prolong QT Interactions
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Medical warning:
Serious. These medicines may interact and cause very harmful effects. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Your medicine may speed up how quickly your liver processes crizotinib. In addition, both of your medicines may affect your heart's rhythm.
What might happen:
The amount of crizotinib in your blood may decrease and it may not work as well.Taking crizotinib and your other medicine together may affect your heart rhythm and increase your risk of irregular heartbeats, which may be life-threatening.
What you should do about this interaction:
Let your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together. Your doctor may want to change your medicines. Let your doctor know right away if you notice an irregular heartbeat or have dizziness or fainting episodes.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
- 1.Xalkori (crizotinib) UK Summary of Product Characteristics. Pfizer Limited July, 2021.
- 2.Sustiva (efavirenz) US prescribing information. Bristol-Myers Squibb Company November, 2023.
- 3.Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, Philippides GJ, Roden DM, Zareba W. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2010 Mar 2;55(9):934-47.
- 4.Abdelhady AM, Shugg T, Thong N, Lu JB, Kreutz Y, Jaynes HA, Robarge JD, Tisdale JE, Desta Z, Overholser BR. Efavirenz Inhibits the Human Ether-A-Go-Go Related Current (hERG) and Induces QT Interval Prolongation in CYP2B6*6*6 Allele Carriers. J Cardiovasc Electrophysiol 2016 Jun 23.
- 5.Abu Rmilah AA, Lin G, Begna KH, Friedman PA, Herrmann J. Risk of QTc Prolongation Among Cancer Patients Treated with Tyrosine Kinase Inhibitors. Int J Cancer. 2020 May 25.
- 6.Tibotec Pharmaceuticals. A Phase I, double-blind, double-dummy, randomized, placebo controlled and active controlled trial to evaluate the effect of TMC278 25 mg q.d. at steady-state and the effect of efavirenz (EFV) 600 mg q.d. at steady-state on the QT/QTc interval. Accessed at: https://clinicaltrials.gov/ct2/show/study/NCT00744809 February, 2010.
- 7.US Food and Drug Administration (FDA). Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at: https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and- drug-interactions-table-substrates-inhibitors-and-inducers. Updated 11/14/2017.
Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.